Loading patent…
AssigneesBecton, Dickinson and Company, Novocell, Inc.
InventorsSharon Presnell, Mohammad Heidaran, Perry Haaland, David Scharp, Paul Latta, Margaret Coutts, Catherine McIntyre
Estimating the term…
This invention relates, e.g., to a method for expanding mammalian acinar cells, comprising culturing the cells in a cell culture system comprising a cell culture medium and a cell attachment surface, under conditions wherein the acinar cells undergo a 3-4 fold expansion together with transdifferentiation into a modified cell phenotype (IP cells) showing characteristics of acinar cells and liver cells. The invention also relates to a method for transforming these IP cells to insulin-producing cells in vitro, comprising culturing the cells in a novel, defined medium. Also disclosed are suitable culture media for performing these methods, isolated cells having the phenotype of IP cells and/or produced by these methods, and kits for performing the methods.
1-10. (canceled)
An isolated insulin-producing cell generated by a method comprising the step of culturing an IP cell in a cell culture medium comprising an effective amount of at least one differentiation promoting factor selected from the group consisting of C-Natriuretic Peptide (CNP), Calcitonin Gene Related Peptide, Cholera Toxin B Subunit, Dexamethasone, Gastrin-Releasing Peptide, Laminin, Met-Enkephalin, PDGFAA+PDGFBB, Sonic Hedgehog, and Substance P, such that the IP cell is transformed into an insulin-producing cell.
An insulin-producing cell, prepared by differentiating a mammalian acinar cell in vitro, wherein said insulin-producing cell has an expression profile after 16 days ex vivo as shown in Table 6.
13-20. (canceled)
Dependencies are inferred from the claim text.